A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

被引：1
|
作者：
Daver, Naval [1 ]
Assi, Rita [1 ]
Ravandi, Farhad [1 ]
Garcia-Manero, Guillermo [1 ]
Jabbour, Elias [1 ]
DiNardo, Courtney D. [1 ]
Kadia, Tapan M. [1 ]
Ning, Jing [2 ]
Nogueras-Gonzalez, Graciela [2 ]
Pierce, Sherry [1 ]
Gombos, Dan [3 ]
Komblau, Steven [1 ]
Konopleva, Marina [1 ]
Kelly, Mary [1 ]
Borthakur, Gautam [1 ]
Zhang, Weiguo [1 ]
Cortes, Jorge [1 ]
Kantarjian, Hagop [1 ]
Andreeffl, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Ophthalmol, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 10期
关键词：
AML; selinexor; sorafenib; FLT3-mutation;
D O I：
10.1016/j.clml.2017.09.034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-025
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [41] Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US
    Aly, Abdalla
    Bapat, Bela
    Ray, Saurabh
    Chen, Zhiyong
    Botteman, Marc
    BLOOD, 2017, 130
  • [42] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Senapati, Jayastu
    Maiti, Abhishek
    Loghavi, Sanam
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Pierce, Sherry A.
    Gonzalez, Graciela M. Nogueras
    Ning, Jing
    Issa, Ghayas C.
    Andreeff, Michael
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2022, 140
  • [43] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Li, Huang
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BLOOD, 2023, 142
  • [44] Y Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes
    Zeidan, Amer M.
    Gilligan, Adrienne M.
    Gautam, Santosh
    Grinblatt, David L.
    Elsouda, Dina
    Sullivan, Loretta
    Pandya, Bhavik J.
    BLOOD, 2020, 136
  • [45] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [46] Novel treatments for relapsed/refractory acute myeloid leukemia with FLT3 mutations
    Tallis, Eran
    Borthakur, Gautam
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (08) : 621 - 640
  • [47] Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)
    Zeidan, Amer M.
    Qi, Cynthia Z.
    Pandya, Bhavik J.
    Garnham, Andy
    Yang, Hongbo
    Shah, Manasee V.
    BLOOD, 2019, 134
  • [48] Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study
    Jin, Jie
    Wang, Huafeng
    Yu, Wen-Juan
    Ge, Zheng
    Wei, Xudong
    Li, Yuhua
    Jiang, Zhongxing
    Li, Yiqing
    Du, Xin
    Yang, Linhua
    Lin, Lie
    Wang, Jishi
    Yao, Yazhou
    Hu, Xiaoping
    Lan, Jianping
    Deng, Xiuzhi
    Chen, Tong
    Feng, Xianqi
    Li, Dengju
    Hou, Ming
    Fu, Rong
    Huang, Siyong
    Wang, Jingbo
    Du, Xin
    Yang, Hui
    Yang, Haiping
    Jiang, Yingzhi
    Wang, Zhijie
    Li, Deng
    Liu, Bing
    Kang, Ning
    Zhuang, Yulei
    Zhang, Yingjun
    BLOOD, 2023, 142
  • [49] Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results
    Cortes, Jorge E.
    Khaled, Samer
    Martinelli, Giovanni
    Perl, Alexander E.
    Ganguly, Siddhartha
    Russell, Nigel H.
    Kramer, Alwin
    Dombret, Herve
    Hogge, Donna
    Jonas, Brian A.
    Leung, Anskar Yh
    Mehta, Priyanka
    Montesinos, Pau
    Radsak, Markus P.
    Sica, Simona
    Arunachalam, Meena
    Holmes, Melissa
    Namuyinga, Ruth
    Zhang, Yufen
    Levis, Mark J.
    ANNALS OF ONCOLOGY, 2019, 30 : 81 - 81
  • [50] Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
    Luger, Selina M.
    Sun, Zhuoxin
    Loghavi, Sanam
    Lazarus, Hillard M.
    Rowe, Jacob M.
    Tallman, Martin S.
    Pratz, Keith W.
    Litzow, Mark
    BLOOD, 2019, 134
12345